Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL1695059 | 0.95 | NPC1 (0.36) | CYP2D6CYP2C19ALDH1A1NPC1RAB9A | |
| SCHEMBL467913 | 0.72 | NPSR1 (0.32) | CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL27987977 | 0.70 | — | — | |
| SCHEMBL28719441 | 0.69 | CYP2D6 (0.41) | CYP2D6CYP2C19TP53ALDH1A1GAA | |
| SCHEMBL7525656 | 0.69 | CYP2D6 (0.41) | CYP2D6CYP2C19TP53ALDH1A1GAA | |
| SCHEMBL42490 | 0.69 | — | — | |
| Ammonia Solution, Strong SCHEMBL29172696 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL10822622 | 0.67 | — | — | |
| SCHEMBL15567040 | 0.67 | — | — | |
| Bromide SCHEMBL11752199 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4014873-A | Process for the production of 7-acylamidocephalosporins | MERCK & CO., INC. (US) | 1977-03-29 | — | — | US | claimed |
| EP-2885300-A1 | TRIS(HETERO)ARYLPYRAZOLES AND USE THEREOF | AiCuris GmbH & Co. KG (DE) | 2015-06-24 | — | — | EP | disclosed |
| WO-2014027112-A1 | TRIS(HETERO)ARYLPYRAZOLES AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2014-02-20 | — | — | WO | disclosed |
| EP-2181996-A1 | Aminopiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2010-05-05 | — | — | EP | disclosed |
| US-20100081650-A1 | Antimicrobial Compounds | AXTEN JEFFREY MICHAEL | 2010-04-01 | — | — | US | disclosed |
| US-7622481-B2 | Antibacterial compounds | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| US-7534793-B2 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2009-05-19 | — | — | US | disclosed |
| EP-1537123-B1 | AMINO-SUBSTITUTED CYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS | GLAXO GROUP LTD (GB) | 2009-04-29 | — | — | EP | disclosed |
| US-7498326-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-03-03 | — | — | US | disclosed |
| US-7312212-B2 | Aminopiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2007-12-25 | — | — | US | disclosed |
| EP-1051413-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2000-11-15 | — | — | EP | disclosed |
| WO-2000043383-A1 | PIPERIDINYLQUINOLINES AS PROTEIN TYROSINE KINASE INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000021952-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2000-04-20 | — | — | WO | disclosed |
| WO-2000021948-A1 | NAPHTHRYDINE COMPOUNDS AND THEIR AZAISOSTERIC ANALOGUES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2000-04-20 | — | — | WO | disclosed |
| WO-1999037635-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 1999-07-29 | — | — | WO | disclosed |
| US-5190922-A | Antiinflammatory | ABBOTT LABORATORIES (US) | 1993-03-02 | — | — | US | disclosed |
| WO-1992021361-A1 | TERMINALLY MODIFIED TRI-, TETRA- AND PENTAPEPTIDE ANAPHYLATOXIN RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 1992-12-10 | — | — | WO | disclosed |
| US-4107432-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1978-08-15 | — | — | US | disclosed |
| US-4058661-A | 7-Diacyl cephalosporins | MERCK & CO., INC. (US) | 1977-11-15 | — | — | US | disclosed |
| US-4014873-A | Process for the production of 7-acylamidocephalosporins | MERCK & CO., INC. (US) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081650-A1 | Antimicrobial Compounds | ELANE, NISCH, PIGS | CYP2D6 831/4885CYP2C19 1842/4885TP53 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.